MedPath

Surgical Treatment of Hypertrophic Obstructive Cardiomyopathy With Severe Mitral Insufficiency.

Not Applicable
Completed
Conditions
Hypertrophic Obstructive Cardiomyopathy
Registration Number
NCT02054221
Lead Sponsor
Meshalkin Research Institute of Pathology of Circulation
Brief Summary

Compare the results of reconstruction and mitral valve replacement in the surgical treatment of obstructive hypertrophic cardiomyopathy with severe mitral insufficiency.

Detailed Description

Many years myoectomy for Morrow was the gold standard in the treatment of obstructive hypertrophic cardiomyopathy. Currently more retrospective data in the literature about the good results the extended septal myectomy. But the question remains what is best for patients with obstructive hypertrophic cardiomyopathy and severe mitral insufficiency: use extended myoectomy with mitral valve repair a or replacement.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
82
Inclusion Criteria
  • Able to sign Informed Consent and Release of Medical Information forms
  • Age ≥ 18 years
  • obstructive hypertrophic cardiomyopathy
  • surgically significant mitral insufficiency
  • II-IV (NYHA),
  • average systolic pressure gradient greater than 50 mm Hg. Art. at rest;
  • basal or medium ventricular obstruction
Exclusion Criteria
  • Related defect of the aortic valve;
  • Organic mitral valve disease (dysplasia, rheumatic fever, infective endocarditis);
  • Surgically significant coronary artery lesions;
  • Patients requiring implantation of a cardioverter-defibrillator

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
The function of the mitral valve (mitral regurgitation return, prosthesis dysfunction)one year
Secondary Outcome Measures
NameTimeMethod
The pressure gradient in the output section of the left ventricleone year

Trial Locations

Locations (1)

Novosibirsk State Research Institute of Circulation Pathology

🇷🇺

Novosibirsk, Novosibirsk territory, Russian Federation

Novosibirsk State Research Institute of Circulation Pathology
🇷🇺Novosibirsk, Novosibirsk territory, Russian Federation

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.